Diabetes
IV mesenchymal stem cell protocols for type 2 diabetes and its complications — neuropathy, slow wound healing, kidney involvement. Integrated with primary-care management, never instead of it.
- Class
- Endocrine
- Approach
- IV systemic, multi-dose
- Materials
- MSC · exosome
- Coordination
- With endocrinology / primary care
01 About
What we mean by "diabetes."
Type 2 diabetes is a metabolic disorder of insulin resistance combined with progressive beta-cell dysfunction. It is the most common form globally and the leading cause of adult blindness, end-stage renal disease, non-traumatic amputation, and a major contributor to cardiovascular mortality. Standard management is glycemic control through diet, exercise, metformin, GLP-1 agonists, SGLT2 inhibitors, and (when needed) insulin.
Stem cell therapy is being studied as an adjunctive intervention — both for glycemic control directly and for the long-term complications (neuropathy, kidney disease, slow wound healing) that drive diabetes-related morbidity.
02 How it works
How regen supports the metabolic system.
Mesenchymal stem cells delivered systemically modulate the chronic, low-grade inflammation that drives insulin resistance and beta-cell dysfunction. They release exosomes that carry anti-inflammatory and pro-regenerative signals across multiple tissues — pancreas, kidney, peripheral nerves, vasculature — addressing the systemic nature of diabetes rather than a single organ.
This is not a replacement for diabetes medications. The realistic expectation is improvement in glycemic markers (HbA1c), modest reductions in insulin requirements, and possibly slowed progression of complications — all alongside continued primary-care management.
03 What the research shows
What the studies show.
Type 2 diabetes has accumulated a meaningful evidence base for MSC therapy — the most consistent signal is on glycemic control, with secondary signals on insulin requirements and complication rates.
Umbilical Cord-Derived MSCs in Chinese Adults with Type 2 Diabetes
A double-blinded, randomized, placebo-controlled phase II trial of 91 patients with type 2 diabetes received intravenous infusion of umbilical cord-derived MSCs or placebo three times at 4-week intervals, followed for 48 weeks. The MSC group showed significant improvements in glycemic control compared with placebo — including reduced HbA1c and reduced insulin requirements.
Read on SpringerMSC Therapy as a Possible Treatment for Diabetes
A 2024 meta-analysis pooled MSC clinical trials in diabetes. Treatment was associated with significant improvements in glycemic control — HbA1c reductions up to 1.45% and reduction in insulin requirements up to 2.05 U/kg/day in the included studies. Safety was consistently established across trials.
Read on FrontiersMSC-Based Therapy for Type 1 & Type 2 Diabetes: Systematic Review
A 2025 systematic review of 13 studies (507 patients — 199 type 1, 308 type 2) of MSC therapy in diabetes. The review consolidated efficacy data and identified the patient subgroups (newly diagnosed, on insulin) most likely to benefit. Safety was confirmed across all included trials.
Read on PubMed Central
Diabetes is one of the more promising systemic indications by clinical-evidence standards. Glycemic control improvements have been reproducible. The next step in the evidence is whether MSC therapy can durably reduce diabetic complication rates — promising but still developing.
04 Are you a candidate
Who's a candidate.
Candidates:
- Type 2 diabetes with HbA1c above target despite optimized medical management.
- Diabetes with progressing complications (neuropathy, nephropathy) seeking adjunct therapy.
- Patients on stable diabetes care with active endocrinology or primary-care follow-up.
- Realistic expectations — glycemic improvement and complication-rate reduction, not cure.
When we will not recommend it:
- Type 1 diabetes — different mechanism, more limited evidence base.
- Acute decompensation (DKA, HHS) — stabilize first.
- Patients seeking to reduce or stop diabetes medications.
- Patients without optimized lifestyle and medication management — fix the foundation first.
Think you might be a candidate?
The first step is a 60–90 minute consultation. We review your imaging, history, and goals — and tell you honestly whether regenerative therapy is the right next step.
05 A patient experience
Dr. Abdullah did an amazing job treating both me and my spouse. I feel less pain every day, and my brain fog is entirely gone. It's only been about 3 weeks.
Kayla Google · Local Guide
07What happens at your consultation
A conversation, not a sales meeting.
-
01
Intake & history
60–90 minutes. We review imaging, prior treatments, current medications, and goals. Most of this hour is listening.
-
02
Focused exam
A clinical exam tailored to your indication. Range of motion, strength, functional testing — what the literature actually predicts response on.
-
03
Honest candidacy review
If we think you're a candidate, we'll tell you why. If we don't, we'll tell you what we'd recommend instead — surgery, PT, watchful waiting.
-
04
Written plan & pricing
A defined treatment plan with modality, sequence, follow-up cadence, and total cost — before any commitment.
06 What treatment looks like
What treatment looks like.
A diabetes protocol begins with primary-care or endocrinology coordination, full labs (HbA1c, fasting glucose, lipid panel, kidney function, urine ACR), and review of medications. Treatment is IV systemic MSC and/or exosome material in a series of doses spaced 4 weeks apart, modeled on the published RCTs.
Reassessment at 3, 6, and 12 months. HbA1c and fasting glucose tracking, insulin and oral medication titration coordinated with the patient's diabetes care team.
09 Common questions
Common questions, answered.
Will this cure my diabetes?
No. Realistic expectation: improved glycemic control, possibly reduced insulin requirements, and slowed complication rates.
Should I stop my diabetes medications?
No. We coordinate with your endocrinologist and titrate medications based on labs.
Does this work for type 1 or type 2?
Strongest evidence for type 2 diabetes. Type 1 has more limited published data — worth a specific conversation.
Can this prevent diabetic complications?
Long-term trials suggest yes, particularly for diabetic neuropathy. The picture is most encouraging with early intervention.
What does the protocol look like?
IV MSC infusions spaced over weeks, modeled on the published phase II trial protocols (typically 3 doses at 4-week intervals).
What are the risks?
IV MSC protocols are well-tolerated in diabetes trials. The published meta-analyses note only minor effects (occasional nausea) — no severe adverse events.
08 Coverage & cost
Most regenerative protocols at Apex are not covered by insurance — we discuss pricing directly, in writing, before any commitment. Softwave shockwave is the exception: covered by Medicare Parts A & B with supplement (not by Medicare Advantage). Financing options are available for protocols not covered. We never hold a pricing conversation until we know you're a candidate.
Begin with a consultation.
A frank conversation about your diabetes, your current management, and whether IV MSC therapy is the right adjunct — and what the trial data actually predicts for your situation.